Exploitation of treatment induced tumor lysis to enhance sensitivity of ctDNA analysis: A first-in-human pilot study Read more about Exploitation of treatment induced tumor lysis to enhance sensitivity of ctDNA analysis: A first-in-human pilot study
Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab +/- chemotherapy in non-small cell lung cancer (NSCLC) Read more about Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab +/- chemotherapy in non-small cell lung cancer (NSCLC)
ctDNA detection in early-stage non-small cell lung cancer Read more about ctDNA detection in early-stage non-small cell lung cancer
Clinical utility of TP53 mutations (TP53m) dynamic monitoring in circulating tumor DNA (ctDNA) in patients (pts) with high-grade ovarian carcinomas (HGOC) Read more about Clinical utility of TP53 mutations (TP53m) dynamic monitoring in circulating tumor DNA (ctDNA) in patients (pts) with high-grade ovarian carcinomas (HGOC)
Residual ctDNA after treatment predicts early relapse in patients with early stage non-small cell lung cancer Read more about Residual ctDNA after treatment predicts early relapse in patients with early stage non-small cell lung cancer
Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial Read more about Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial
Sensitive detection of ctDNA in early-stage non-small cell lung cancer patients with a personalized sequencing assay Read more about Sensitive detection of ctDNA in early-stage non-small cell lung cancer patients with a personalized sequencing assay
Role of circulating tumor DNA (ctDNA) from Liquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation (LIBERTI) Read more about Role of circulating tumor DNA (ctDNA) from Liquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation (LIBERTI)
Circulating tumor DNA (ctDNA) clearance as a biomarker in patients with locally advanced NSCLC following chemoradiation Read more about Circulating tumor DNA (ctDNA) clearance as a biomarker in patients with locally advanced NSCLC following chemoradiation
Residual ctDNA after treatment predicts early relapse in patients with early stage non-small cell lung cancer Read more about Residual ctDNA after treatment predicts early relapse in patients with early stage non-small cell lung cancer